Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02085304 · ClinicalTrials.gov registry record · Phase 1
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
A Phase 1 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02085304 is a Phase 1 study that was terminated before completion, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 8 participants.
The verdict
NCT02085304, a Phase 1 study, was terminated before completion, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control. Recent studies show that survival improves for patients who get aggressive surgery to remove a tumor before starting radiation (RT) and chemotherapy (chemo) treatment. Surgery, RT and chemo are part of regular cancer care for GBM. RT is usually done in daily doses 5 days a week over about 6 weeks. Beams of radiation are aimed at the tumor site plus some of the normal brain tissue around the tumor area. GammaKnife® (GK) radiosurgery also delivers radiation but in a larger dose over one day. GK sends beams to a precise target (tumor location) and very little normal brain tissue that is nearby. This study will compare GK treatment to the usual RT treatment after surgery, and with chemo. We want to know: * How well each treatment keeps the tumor from growing back. * What the effects (good and bad) of the treatments are. * How you rate your quality of life. * How the treatment affects your ability to think, understand, reason, and remember. * How you rate your ability to think, understand, reason, and remember. * If using a certain type of MRI scan can show the difference between new tumor growth and changes caused by treatment. * If certain features found in tumor cells can help doctors predict how tumors will respond to treatment.
Interventions
- DRUG Temozolomide
- PROCEDURE Gross total resection and Gliadel(R) wafers implanted
- RADIATION GammaKnife(R) stereotactic Radiosurgery
- RADIATION Standard fractionated radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05-07 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02085304
The ClinicalTrials.gov registry entry for NCT02085304 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT02085304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02085304 about?
NCT02085304 is a clinical study titled "Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM". A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control. Recent studies show that survival improves for patients who get aggressive surgery to remove a tumor before starting radiation (RT) and chemotherapy (chemo) treatment. Surgery, RT and chemo are part...
What is the current status of trial NCT02085304?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-05-07. Estimated completion is 2018-05-29.
What interventions are being tested in trial NCT02085304?
The interventions under investigation include: Temozolomide (DRUG), Gross total resection and Gliadel(R) wafers implanted (PROCEDURE), GammaKnife(R) stereotactic Radiosurgery (RADIATION), Standard fractionated radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02085304?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.